Abivax S.A. (ABVX) stock

ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 1/30

$90.20−1.24 (-1.36%)

Close on Nov 12, 2026Market cap $7.08BP/E –Yield –

Abivax statistics

49 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: –

Valuation ratiosIndustry

Market Cap: €6.44B; €804.14M
Enterprise Value: €6.05B; €571.68M

Share statisticsIndustry

Shares Outstanding: 79M; 100M
Shares Change (YoY): 10.3%; 5.61%
Shares Change (QoQ): 0.66%; –
Float: 75M; 79M
Shares Held by Insiders: 4.50%; 9.05%
Shares Held by Institutions: 70.1%; 20.8%

Short sellingIndustry

Short Interest: 4M; –
Short Interest Change: -43.3%; -2.55%
Days to Cover: 4.63; 3.54

Stock price statisticsIndustry

Price Change (1 Week): 2.18%; 2.02%
Price Change (1 Month): 6.05%; 8.16%
Price Change (3 Months): -24.7%; -13.7%
Price Change (6 Months): -25.0%; -4.97%
Price Change (YTD): -32.2%; -8.54%
Price Change (1 Year): -13.8%; -15.2%
Price Change (3 Years): 770.9%; -8.79%
Average Volume (10 Days): 776,763; –
Average Volume (20 Days): 894,626; –
Average Volume (90 Days): 1M; –
Relative Volume: 0.70; 0.70
Relative Strength Index (14): 51.7; 55.5
Volatility (1 Year): 86.4%; 65.1%
Beta (5 Years): 2.26; 0.87

Returns on capitalIndustry

Return on Capital Employed (ROCE): -63.0%; -23.8%

Financial positionIndustry

Current Ratio: 5.97; 3.49
Quick Ratio: 5.41; 1.51
Interest Coverage: -2.20; -0.71

EfficiencyIndustry

Employee Count: 69; 304
WACC: 16.2%; 9.36%

Income statement (TTM)Industry

Operating Income: -€246.06M; -€54.01M
Pretax Income: -€330.25M; -€47.40M
EBITDA: -€244.98M; -€42.85M
EPS (Diluted): -4.83 EUR; -0.55 EUR

Balance sheetIndustry

Cash & Short-Term Investments: €387.99M; €199.29M
Net Cash (Debt): €387.99M; €111.50M
Net Cash Per Share: 4.94 EUR; 1.53 EUR
Working Capital: €355.94M; €119.55M

Cash flow (TTM)Industry

Operating Cash Flow: -€161.13M; -€42.16M
Capital Expenditures: -€142.00K; -€2.34M
Free Cash Flow: -€161.27M; -€52.90M
FCF Per Share: -2.05 EUR; -0.48 EUR

Dividends and yieldsIndustry

FCF Yield: -2.50%; -13.2%
Buyback Yield: -10.1%; -10.6%
Shareholder Yield: -10.1%; -10.6%

Taxes and interestIndustry

Interest Expense: €111.74M; €55.20M
Income Tax: €5.85M; €80.00K

Scores and fair valueIndustry

Altman Z-Score: 39.43; 1.20

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	ABVX	S&P 500	Difference	ABVX per year	S&P 500 per year
1 month	+3.7%	-2.7%	+6.4 pts
3 months	-28.1%	-1.7%	−26.4 pts
Year to date	-33.1%	+11.9%	−45.0 pts
1 year	-12.8%	+12.0%	−24.8 pts
3 years	+802.0%	+78.2%	+723.8 pts	+108.2%	+21.2%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

4M ABVX shares were sold short on Oct 30, 2026, down 43.3% from the previous report. At recent volumes it would take 4.6 days to buy them back. Over the last 20 sessions, 33.4% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	4,110,784	-43.3%	888,647	4.6
Oct 15, 2026	7,254,941	-6.7%	1,192,395	6.1
Sep 30, 2026	7,776,429	+13.4%	1,540,598	5.0
Sep 15, 2026	6,858,511	-1.5%	1,114,113	6.2
Aug 31, 2026	6,962,029	+16.0%	873,629	8.0
Aug 14, 2026	6,001,787	+15.5%	765,619	7.8
Jul 31, 2026	5,194,797	+29.3%	1,029,141	5.0
Jul 15, 2026	4,018,322	-7.1%	1,705,540	2.4
Jun 30, 2026	4,325,904	-11.5%	2,991,256	1.4
Jun 15, 2026	4,887,145	+60.0%	4,102,529	1.2
May 29, 2026	3,053,530	+23.1%	1,212,239	2.5
May 15, 2026	2,480,049	-2.6%	833,182	3.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?